TickerFacts.

Intellia Therapeutics, Inc. (NTLA): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$431.22M
Year ended 2025-12-31
-$414.40M
Trailing 12 months to 2026-06-30
2015-12-31: -$13.08M2016-12-31: -$31.05M2017-12-31: -$66.56M2018-12-31: -$86.41M2019-12-31: -$100.78M2020-12-31: -$130.27M2021-12-31: -$260.96M2022-12-31: -$450.59M2023-12-31: -$506.31M2024-12-31: -$523.98M2025-12-31: -$431.22M-$431.22M
2015-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$431.22Mn/m2026-02-26, From 2025-01-01
2024-12-31-$523.98Mn/m2026-02-26, From 2024-01-01
2023-12-31-$506.31Mn/m2026-02-26, From 2023-01-01
2022-12-31-$450.59Mn/m2025-02-27, From 2022-01-01
2021-12-31-$260.96Mn/m2024-02-22, From 2021-01-01
2020-12-31-$130.27Mn/m2023-02-23, From 2020-01-01
2019-12-31-$100.78Mn/m2022-02-24, From 2019-01-01
2018-12-31-$86.41Mn/m2021-02-26, From 2018-01-01
2017-12-31-$66.56Mn/m2020-02-27, From 2017-01-01
2016-12-31-$31.05Mn/m2019-02-27, From 2016-01-01
2015-12-31-$13.08Mn/a2018-03-14, From 2015-01-01

EBITDA at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$431.22Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$10.63Mn/m
Immucell Corp (ICCC)2025-12-31$4.43M+306.8%
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.80Mn/m
Myriad Genetics Inc (MYGN)2025-12-31-$333.50Mn/m
Neogen Corp (NEOG)2026-05-31$94.70Mn/m
Biomerica Inc (BMRA)2026-05-31-$5.24Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$48.93Mn/m
Lantheus Holdings, Inc. (LNTH)2025-12-31$380.93M-27.0%

Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗